Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
580.70
+1.09 (0.19%)
At close: Aug 29, 2025, 4:00 PM
582.00
+1.30 (0.22%)
After-hours: Aug 29, 2025, 7:59 PM EDT

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

The 23 analysts that cover Regeneron Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $794.83, which forecasts a 36.87% increase in the stock price over the next year. The lowest target is $547 and the highest is $1,175.

Price Target: $794.83 (+36.87%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$547$794.83$800$1,175
Change-5.80%+36.87%+37.76%+102.34%

Analyst Ratings

The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingMar '25Apr '25May '25Jun '25Jul '25Aug '25
Strong Buy767766
Buy121211111110
Hold655556
Sell111111
Strong Sell000000
Total262424242323

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Bernstein
Bernstein
Buy
Maintains
$753$781
BuyMaintains$753$781+34.49%Aug 27, 2025
Jefferies
Jefferies
Strong Buy
Maintains
$813$831
Strong BuyMaintains$813$831+43.10%Aug 27, 2025
Truist Securities
Truist Securities
Strong Buy
Maintains
$940$812
Strong BuyMaintains$940$812+39.83%Aug 11, 2025
BMO Capital
BMO Capital
Buy
Maintains
$600$640
BuyMaintains$600$640+10.21%Aug 4, 2025
Morgan Stanley
Morgan Stanley
Buy
Maintains
$754$761
BuyMaintains$754$761+31.05%Aug 4, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
14.16B
from 14.20B
Decreased by -0.27%
Revenue Next Year
14.87B
from 14.16B
Increased by 4.97%
EPS This Year
39.96
from 38.34
Increased by 4.24%
EPS Next Year
42.27
from 39.96
Increased by 5.77%
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
8.50B16.07B12.17B13.12B14.20B14.16B14.87B
Revenue Growth
29.58%89.14%-24.26%7.76%8.27%-0.27%4.97%
EPS
30.5271.9738.2234.7738.3439.9642.27
EPS Growth
65.33%135.81%-46.90%-9.03%10.27%4.24%5.77%
Forward PE
-----14.5313.74
No. Analysts
-----3129
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High15.3B16.3B
Avg14.2B14.9B
Low13.3B12.8B

Revenue Growth

Revenue Growth20252026202720282029
High
7.6%
15.2%
Avg
-0.3%
5.0%
Low
-6.4%
-9.9%

EPS Forecast

EPS20252026202720282029
High44.5256.75
Avg39.9642.27
Low34.3028.78

EPS Growth

EPS Growth20252026202720282029
High
16.1%
42.0%
Avg
4.2%
5.8%
Low
-10.5%
-28.0%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.